Primary Ovarian Insufficiency Nationwide Incidence Rate and Etiology Among Israeli Adolescents.


Journal

The Journal of adolescent health : official publication of the Society for Adolescent Medicine
ISSN: 1879-1972
Titre abrégé: J Adolesc Health
Pays: United States
ID NLM: 9102136

Informations de publication

Date de publication:
05 2020
Historique:
received: 31 08 2019
revised: 13 11 2019
accepted: 27 11 2019
pubmed: 29 1 2020
medline: 25 6 2021
entrez: 29 1 2020
Statut: ppublish

Résumé

The aim of the study was to estimate the current incidence and the distribution of etiologies of primary ovarian insufficiency (POI) in a nationwide study. The prevalence of POI in young adult women has recently increased, but the data cited for adolescents are more than three decades old. Data regarding females aged <21 years diagnosed with POI during the years 2000-2016 were collected from all the pediatric endocrinology units in Israel. POI was defined by at least 4 months of amenorrhea in association with menopausal levels of follicle-stimulating hormone. Iatrogenic cases were excluded. For the 130 females aged <21 years included in the study, the distribution of POI etiologies was Turner syndrome/mosaicism in 56 (43%), idiopathic in 35 (27%), and other (developmental, genetic, metabolic, adrenal, and autoimmune) in 39 (30%) females. During the years 2009-2016, compared with 2000-2008, the incidence rate of new POI diagnoses per 100,000 person-years doubled (4.5 vs. 2.0; p value <.0001), and incidence rates of idiopathic and other etiologies increased by 2.6 (p value = .008) and 3.0 (p value = .002), respectively. In contrast, the incidence of Turner syndrome was constant (p value = .2). In the age group of 15-21 years, the current incidence of non-Turner POI in adolescents is one per 100,000 person-years. In this nationwide study, the incidence rate of POI in youth aged <21 years was one tenth of the rate that is commonly cited. A significant increase in the rate of POI in non-Turner females was observed over the last decade. Contributions of environmental and epigenetic factors should be studied.

Identifiants

pubmed: 31987720
pii: S1054-139X(19)30923-1
doi: 10.1016/j.jadohealth.2019.11.315
pii:
doi:

Substances chimiques

Follicle Stimulating Hormone 9002-68-0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

603-609

Informations de copyright

Copyright © 2019 Society for Adolescent Health and Medicine. Published by Elsevier Inc. All rights reserved.

Auteurs

Noah Gruber (N)

Pediatric Endocrine and Diabetes Unit, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Ramat Gan, Israel; Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel. Electronic address: noahgruber@gmail.com.

Shir Kugler (S)

Pediatric Endocrine and Diabetes Unit, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Ramat Gan, Israel; Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel.

Liat de Vries (L)

Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel; The Jesse Z and Sara Lea Shafer Institute for Endocrinology and Diabetes, Schneider Children's Medical Center of Israel, Petach Tikva, Israel.

Avivit Brener (A)

Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel; The Jesse Z and Sara Lea Shafer Institute for Endocrinology and Diabetes, Schneider Children's Medical Center of Israel, Petach Tikva, Israel.

Amnon Zung (A)

Pediatric Endocrinology Unit, Kaplan Medical Center, Rehovot, Israel; The School of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.

Ori Eyal (O)

Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel; Pediatric Endocrinology and Diabetes Unit, Dana-Dwek Children Hospital, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.

Marianna Rachmiel (M)

Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel; Pediatric Endocrinology Unit, Assaf Haroffeh Medical Center, Zerifin, Israel.

Ilana Koren (I)

Pediatric Clinic, Armon Child Center, Clalit Health Services, Haifa, Israel.

Yardena Tenenbaum-Rakover (Y)

Pediatric Endocrine Unit, Ha'Emek Medical Center, Affula, Israel; The Rappaport Endocrinology Faculty of Medicine, Technion, Haifa, Israel.

Eli Hershkovitz (E)

Pediatric Endocrinology and Metabolic Unit, Soroka University Medical Center, Israel and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel.

Zohar Landau (Z)

Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel; Pediatric Endocrine and Diabetes Unit, E. Wolfson Medical Center, Holon, Israel.

Meirav Oren (M)

Paediatric Endocrine Unit, Rambam Health Care Campus, Haifa, Israel.

Alon Eliakim (A)

Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel; Pediatric Department, Meir Medical Center, Kfar Saba, Israel.

David Zangen (D)

The School of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel; Division of Pediatric Endocrinology, Hadassah Hebrew University Medical Center, Jerusalem, Israel.

Alina German (A)

Pediatric Department, Bnei Zion Medical Center, Haifa, Israel.

Hussein Majdoub (H)

Pediatric Clinic, Armon Child Center, Clalit Health Services, Haifa, Israel.

Kineret Mazor-Aronovitch (K)

Pediatric Endocrine and Diabetes Unit, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Ramat Gan, Israel; Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel.

Dalit Modan-Moses (D)

Pediatric Endocrine and Diabetes Unit, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Ramat Gan, Israel; Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel.

Yonatan Yeshayahu (Y)

Pediatric Endocrine and Diabetes Unit, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Ramat Gan, Israel; Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel.

Larisa Naugolni (L)

Pediatric Endocrinology Unit, Assaf Haroffeh Medical Center, Zerifin, Israel.

Yael Levy-Shraga (Y)

Pediatric Endocrine and Diabetes Unit, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Ramat Gan, Israel; Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel.

Michal Ben-Ami (M)

Pediatric Endocrine and Diabetes Unit, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Ramat Gan, Israel; Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel.

Gherta Brill (G)

Migdal Hamea Health Services, Clalit Health Services, Tel Aviv, Israel.

Nehama Zuckerman-Levin (N)

The Rappaport Endocrinology Faculty of Medicine, Technion, Haifa, Israel; Institute of Diabetes, Endocrinology and Metabolism, Rambam Medical Center, Haifa, Israel.

Floris Levy-Khademi (F)

The School of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel; Division of Pediatric Endocrinology, Shaare Zedek Medical Center, Jerusalem, Israel.

Carmit Avnon-Ziv (C)

The School of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel; Division of Pediatric Endocrinology, Shaare Zedek Medical Center, Jerusalem, Israel.

Dov Tiosano (D)

The Rappaport Endocrinology Faculty of Medicine, Technion, Haifa, Israel; Paediatric Endocrine Unit, Rambam Health Care Campus, Haifa, Israel.

Shira Harel (S)

Maccabi Health Services, Central District, Tel Aviv, Israel.

Einat Kedem (E)

Pediatric Endocrine and Diabetes Unit, E. Wolfson Medical Center, Holon, Israel.

Anat Segev-Becker (A)

Pediatric Endocrinology and Diabetes Unit, Dana-Dwek Children Hospital, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.

Yehuda Shoenfeld (Y)

Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel; Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Israel.

Orit Pinhas-Hamiel (O)

Pediatric Endocrine and Diabetes Unit, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Ramat Gan, Israel; Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH